Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
90-Day Safety Study of CG5503 Immediate Release vs Oxycodone Immediate Release in Chronic Pain
2006-003278-93Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tapentadol in chronic pain, lumbodynia (LBP), hip osteoarthritis and 1 more (2 arms), sponsored by Johnson & Johnson. Started Nov 2006; status: completed.
02
Drugs
tapentadol
03
Conditions
chronic painlumbodynia (LBP)hip osteoarthritisknee osteoarthritis (OA)
Beyond the preview
Go deeper on 2006-003278-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003278-93.